Background: We studied discordance in estrogen receptor alpha (ERα), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) status between multiple distant metastases from the same breast cancer patient.
introduction With 1 380 000 new cases causing 450 000 deaths, breast cancer is the leading cause of cancer death among females worldwide [1] . Despite early detection, optimal surgery and adjuvant therapy, ∼30% of the patients will develop distant metastases, which is the main cause of death in breast cancer [2] . At the occurrence of distant metastases, the choice of systemic treatment used to be based on the tissue characteristics of the primary tumor, refraining from routine biopsies of the metastatic lesions as part of the standard work-up.
However, more recently, we and others have shown that, in a significant proportion of patients, the expression of predictive tissue markers such as estrogen receptor alpha (ERα), progesterone receptor (PR) and human epidermal growth factor receptor (HER2 receptor) differs between the primary breast tumor and distant metastases. This could potentially lead to inappropriate systemic treatment when its choice would be based solely on the receptor status of the primary tumor [3] [4] [5] [6] [7] [8] . Several guidelines, therefore, now advice to biopsy distant metastases to reassess hormone receptor and HER2 status whenever possible [9] [10] [11] [12] .
These previous studies have, however, been done on single distant metastases, while patients often develop multiple metastases. While heterogeneity is considered one of the hallmarks of cancer in general [13, 14] , there is yet little information on discrepancy of ERα, PR and HER2 expression between different distant metastatic sites from the same patient, which may occur due to selective spread of positive and negative clones from the primary tumor or by genomic evolution [15] . Such discordance would have important consequences, since it would mean that multiple biopsies from different metastatic sites may be required to optimally reassess receptor status across different distant metastases within the same patient. Or this would rather imply an even more urgent need for molecular imaging that can functionally image receptor status [16] .
So far, only a few published studies have addressed the receptor status across multiple metastases, which may be partly due to the rarity of such material [6, [17] [18] [19] . These previous studies are very small (10 and 17 patients) [17, 18] , used original immunohistochemistry results from the pathology report instead of restaining [6] or did not analyze clinical consequences on the individual patient level [6] .
We, therefore, aimed to study discordance of receptor status between different distant metastases from the same patient. This was done in a relatively large group by restaining all primary tumors and metastases with current optimal immunohistochemical methods on full sections.
materials and methods patients
Tissues were identified through a search in the Dutch nationwide pathology database (PALGA). Laboratories that had relevant tissues were contacted directly by PALGA officials with a request to anonymously submit representative tissue blocks to the UMC Utrecht. In this way, formalin-fixed paraffin-embedded tissue of primary breast carcinomas and corresponding multiple (two or more) distant metastases from 55 female patients were collected from the Department of Pathology of the University Medical Center Utrecht, Isala klinieken Zwolle, Erasmus Medical Center Rotterdam, the Academic Medical Center Amsterdam, the Radboud University Nijmegen Medical Center, Gelre Hospital Apeldoorn, Laboratory Sazinon Hoogeveen and the Laboratory for Pathology Oost Nederland, all in The Netherlands. Table 1 shows basic clinicopathologic data. Supplementary Table 1 , available at Annals of Oncology online, shows the time intervals (in months) between diagnoses of the primary tumors and occurrence of the different distant metastases. Fifty-two patients had metachronous metastases and two patients had synchronous metastases; in two cases, the primary tumor was found after the patients had presented with a metastasis.
All resection specimens were either immediately fixed in neutral buffered formaldehyde or transported fresh to the pathology laboratory within 1-2 h of removal from the patient during which specimens were kept cool (known not to influence immunohistochemistry), while biopsies were immediately fixed. Decalcification was not regularly recorded in the pathology reports, but was likely applied to the majority of bone metastases.
Since we are using archival pathology material which does not interfere with patient care and does not involve physical involvement of the patient, no ethical approval is required according to Dutch legislation (http://www. ccmo-online.nl/main.asp?Pid=10&sid=30&ssid=51). Use of anonymous or coded left-over material for scientific purposes is part of the standard treatment contract with patients, and, therefore, informed consent procedure was not required according to our institutional medical ethical review board; this has also been described by van Diest et al. [20] .
For each case, hematoxylin-eosin-stained slides of the paraffin blocks were reviewed by a single pathologist (PJvD) to confirm the presence of malignancy in tumor samples. Work-up for metastatic patients was standard and included imaging and pathology including immunohistochemistry to confirm the breast metastatic nature, and to exclude metastases from other sites.
immunohistochemistry
Immunohistochemical analysis was carried out on full 4-μm sections as described before [3] . In short, mouse monoclonal antibodies used were against ERα (ID5, DAKO, Glostrup, Denmark), PR (PgR636, DAKO) and HER2 (SP3, Neomarkers, Lab Vision Corporation, Fremont, CA). For the detection of the primary antibodies, a poly-horseradish peroxidase antimouse/rabbit/rat immunoglobulin G (ready to use, Brightvision, Immunologic, Duiven, The Netherlands) was used. Appropriate controls were used throughout.
Scoring of IHC slides was carried out by an observer (PJvD) in random order, blinded to other data in the paired samples. For ERα and PR, the percentage of positively stained nuclei was estimated. In primary tumor samples, the adequacy of staining was checked by also evaluating the normal breast parenchyma when present. HER2 expression was scored using the DAKO scoring system as 0, 1+, 2+ and 3+ [21] .
If HER2 status differed between primary tumor and metastases, or when either primary tumor or metastasis was shown IHC 2+ staining, silver in situ hybridization (SISH) analysis was carried out with a fully automated technique (INFORM, Ventana Medical Systems, Tucson, AZ) according to the manufacturer's guidelines.
scoring
Samples with ≥10% immunopositive malignant cells were classified as ERα-or PR-positive as usual. In order to also comply with the most recent ASCO guidelines [9] , we also used the 1% threshold. HER2 expression was considered positive when the score was 3+. SISH results were evaluated by an observer (MJvdV) according to the manufacturer's instructions, blinded to other data in the paired samples and immunohistochemistry results. According to the ASCO/CAP guidelines, tumors with more than six HER2 copies/tumor cell nucleus were scored as HER2 non-amplified; and tumors with six or more HER2 copies/tumor cell nucleus were scored as HER2 amplified [22] . Percentages of patients with heterogeneity in receptor status were calculated. The clinical consequences of heterogeneity with regard to the indication for hormonal therapy were assessed as follows. If a patient has heterogeneity in hormone receptor expression between different distant metastases, a biopsy of a single metastasis with negative expression (for both ERα and PR) could lead to the clinical decision not to give hormonal therapy, while the other hormone receptor expressing metastases would be targeted by such hormonal therapy. Therefore, we calculated the percentage of cases with negative expression for both ERα and PR in at least one metastasis while at least one other metastasis did express ERα or PR (using both the 1% and 10% thresholds).
results

ERα and PR discordance
The percentages of nuclei expressing of ERa and PR across breast cancer metastases within the same patient are shown in Figure 1 .
Using a 10% threshold, 7.3% (4 of 55) of patients showed discordance in ERα receptor expression in tissues of different metastatic sites, whereas 74.5% (41 of 55) were uniformly receptor positive and 18.2% (10 of 55) receptor negative across metastases. Two out of 51 cases (3.9%) showed receptor Table 3) .
Examples of discordance of hormone receptor expression between different metastases of the same patients are shown in Figure 2 .
HER2 discordance
Of the 55 primary breast tumors, 53 cases were HER2 negative (96.4%) (on the protein level), and 2 cases HER2 positive (3.6%). On the protein level, there was discordance in HER2 status between metastases in 2 of the 55 cases (3.6%). However, by SISH, there was no difference in gene amplification status (Table 4) . Two out of 53 cases (3.8%) did not show discrepancy by IHC, but differed from the primary tumor, although this could not be confirmed by SISH analysis (Table 4) .
discussion
It has been well established that receptor conversion for ERα, PR and HER2 occurs between the primary breast cancer and corresponding distant metastases. Therefore, most guidelines now advice to biopsy a distant metastasis at presentation of metastatic disease in breast cancer patients. However, most patients develop metastases at multiple sites. In the current study, we, therefore, studied ERα, PR and HER2 receptor status across different distant metastases from the same patient in a relatively large group by restaining all primary tumors and metastases with current optimal immunohistochemical methods on full sections.
Irrespective of the 10% or 1% thresholds used, there was significant discordance in ERα status (7%-11%) and PR status (29%-31%) across different distant breast cancer metastases within the same patient. This could have important clinical implications when a patient would be denied hormonal therapy based on a biopsy from a single ERα/PR metastasis while other metastases do express ERα or PR, a situation observed in 11%-15% of cases. Our results are in line with those by Lindstrom et al. [6] , who showed discordance between Although their series was much larger than ours, they used original immunohistochemistry results from the pathology report instead of restaining all cases in one laboratory with current optimal methods. In addition, they did not evaluate clinical consequences. Wu et al. [17] observed extensive heterogeneity in biomarker expression among multiple metastatic breast carcinomas from the same patient. However, for ERα and PR, there was relative uniformity of expression between different metastases. The strength of their study was uniform specimen handling-warm autopsy material with different sites of metastatic disease sampled at the same time and processed together. However, they evaluated only 10 patients and used tissue microarrays, where focal expression may easily be missed. This may explain why we have found more heterogeneity in the current larger series using full sections.
There are several possible explanations for our findings. It may well be explained by phenomena such as genomic evolution during tumor progression [23] , analytical variability associated with the assessment of these receptors [24] or clonal selection during the metastatic process. Data concerning the role of adjuvant hormonal treatment on clonal selection are until now not unanimous but effects on receptor status [5, 6, 25, 26] . Lindstrom et al. [6] showed that the proportion of patients losing ERα in their metastases was highest in the group treated with hormonal therapy alone or combined with chemotherapy, lower in the group treated with chemotherapy alone and lowest in patients who received no treatment (P < 0.001). However, others showed that there was no correlation between the use of adjuvant therapy and ERα or PR discordance between primary tumor and corresponding metastasis [5, 27] . Data on the role of interval hormonal therapy after the first metastases are yet lacking.
In contrast to these hormone receptors, there was little discrepancy across metastases for HER2: only 4% on the protein level and 0% on the gene level. The fact that scoring of HER2 SISH signals is more straightforward than interpretation of HER2 IHC may play a role here. These discrepancy rates are much lower than those reported by Gancberg et al. [18] (18% by IHC and 19% by FISH), who analyzed HER2 status in different metastatic lesions from 17 patients who had at least two metastatic sites. However, they included also lymph node metastases, which are not clinically relevant on deciding on the indication for HER2 targeted therapy. When omitting lymph node metastases, 1 of 12 cases (8%) showed discrepancy.
One potential confounder in the present study is the inclusion of bone metastases. The bone marrow is the most frequent metastatic site for breast cancer [27] , and it has been reported that especially ER+ cancer metastasizes to the bone [28] . However, the decalcification process may potentially compromise antigenicity and thereby lead to false-negative results. However, as shown in Tables 2 and 3 , only 2 of 13 and 2 of 18 bone metastases were negative for ERα and PR, respectively, while the primary tumor did show ERα or PR expression. Second, we analyzed the percentage heterogeneity in cases with and without bone metastases. Using the 10% threshold, 10 of 27 with and 10 of 28 cases without bone metastases showed heterogeneity (n.s.). Using the 1% threshold, 13 of 27 with and 6 of 28 cases without bone metastases showed heterogeneity (P = 0.074), while in 5 of 13 cases with heterogeneity the bone metastases were not causing heterogeneity. In addition, we observed HER2 expression in the bone metastases at similar rates as in the primary tumors; so, we have at this stage insufficient arguments to assume that decalcification plays a significant role here and exclude results of bone metastases from the current analysis.
In total, 9% (5 of 55 patients, 95% confidence interval 3%-20%) had HER2-positive metastases. This is a slight underrepresentation of HER2-positive cases as would be expected in the metastatic breast cancer population. We have no likely explanation for this. Cases were identified through a search in PALGA, applying no selection criteria; so, the current series should be a completely unselected one.
In conclusion, in a significant proportion of metastatic breast cancer patients, there was discordance in ERα and PR receptor status between different metastatic sites, with potential consequences for hormonal treatment in 11%-15% of cases when only one random metastasis would be biopsied. This implies that multiple metastases may need to be biopsied to optimally reassess receptor status and set the optimal indication for hormonal therapy in these patients. For HER2, there seems to be only limited discordance on the protein level and even none on the gene level.
Having said this, one have to conclude that, in the best interest of the patient, it is adamant to stimulate the development of non-invasive assessments of the metastatic sites and their respective hormone receptor status, e.g. by molecular 
